Transbiotech

Name

Transbiotech

Legal name

TransBIOTech

Website

https://transbio.tech

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Preclinical Contract Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industries

Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC), Translational Medicine & Biomarkers (HLAIALAF)

Keywords

• Preclinical research services
• Contract research organization
• Biotechnology R&D
• Animal model studies
• Analytical bioanalysis

Headquarters

HQ city

Lévis

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Research and Development Services: Project-based preclinical research services including bioanalysis, cellular assays, animal models, and custom development for biotech, pharmaceutical, cosmetics, and natural health products companies. Revenue generated through service contracts with private sector and academic partners.
2. Financial Support Facilitation: As a CCTT (College Technology Transfer Center), Transbiotech helps clients access government funding programs including RDA, PARI, PART, FRQ, and tax credits up to 80% of billable costs

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Transbiotech provides preclinical contract research services to biotech, pharmaceutical, cosmetics, and natural health products companies. The organization delivers in vitro cell assays, in vivo animal model studies in a CCPA-accredited facility, preclinical bioanalysis using chromatography and mass spectrometry, and custom method development. It also facilitates access to government R&D funding programs covering up to 80% of project costs through its CCTT (Centre Collégial de Transfert de Technologie) status.

Product overview

Transbiotech is a non-profit biotechnology research organization (CCTT - Centre Collégial de Transfert de Technologie) affiliated with Cégep de Lévis, Quebec, providing preclinical contract research services since 1999. The company offers an integrated portfolio of laboratory services including: Cell Assays (in vitro cell and biochemical testing), Preclinical Bioanalysis (chromatography and mass spectrometry), Animal Models (in vivo pharmacology in CCPA-accredited facility), Custom Development (tailored assay development), and Financial Support (R&D funding assistance). These core services are organized around six scientific expertise areas: Cell Biology, Analytical Chemistry, Immunology, Inflammation, Microbiology, and Pharmacology. The company serves the pharmaceutical, cosmetic, and natural health products sectors. Key laboratory equipment installations include analytical/bioanalytical laboratories with mass spectrometry systems (TQD, TQS, TQS-micro), the IncuCyte S3 real-time imaging system, SAPPHIRE biomolecular imager, Pannoramic MIDI II slide scanner, LSRFortessa X-20 flow cytometer, IVIS Lumina XR animal imaging system, and BugBox anaerobic chamber.

Differentiator

Problem solved

Functional benefit

Products and services

• Cell Assays (Essais cellulaires) In cellulo and in vitro cell and biochemical assays performed on cell lines, primary cells, spheroids, and reconstructed human tissues for evaluating biological efficacy, toxicity, and biomarker detection. Serves biotech, pharmaceutical, cosmetics, and natural health products companies.
• Preclinical Bioanalysis (Bioanalyse préclinique) Preclinical bioanalytical services for quantifying metabolites in various matrices (plasma, urine, tissues) using chromatography and mass spectrometry equipment. Supports pharmacokinetics, ADME, and biodistribution studies for drug development clients.
• Animal Models (Modèles animaux) In vivo pharmacology studies using validated preclinical models for inflammatory diseases, pulmonary inflammation, fibrosis, joint pain, oncology, neurodegenerative diseases, metabolic disorders, skin diseases, and pharmacokinetics/toxicology studies in a CCPA-accredited animal facility.
• Custom Development (Développement sur mesure) Custom assay and method development tailored to specific client project requirements, including custom biochemical or cellular assay development for novel research applications.
• Financial Support (Soutien financier) Assistance in obtaining funding for R&D projects through various government programs including RDA, PARI, PART, FRQ, and tax credits covering up to 80% of billable costs. Helps clients access Canadian federal and provincial research funding.

Quantifiable outcome

• 100+ research projects completed annually with 50+ partners
• +2 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature10 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Feldan ThérapeutiquescoreStrategic or Co-development Partner · 12 March 2026Three-year collaboration on intralesional tumor treatment development funded by $450,000 NSERC research grant. Transbiotech conducts in vivo experiments for Feldan's therapeutic candidates. Partnership builds on nearly 10 years of collaboration supporting Feldan's intracellular delivery platform.
• Cégep de LéviscoreStrategic or Co-development PartnerParent institution and affiliated CCTT. Provides institutional framework, student integration, and research infrastructure. Cégep de Lévis ranked 18th among Canada's Top 50 Research Colleges 2025.
• BienaminorStrategic or Co-development PartnerCollaboration awarded $300,000 grant to advance population health and microbiome-based innovation research.
• BioQuebecminorGTM or Marketing PartnerMember of Quebec biotechnology industry association for networking and industry advocacy.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Altasciences: Canadian preclinical and clinical CRO headquartered in Laval, Quebec, offering integrated drug development services from preclinical through Phase I/IIa. Highly comparable to Transbiotech given shared Quebec base, preclinical service focus, and biotech/pharma client base, though Altasciences operates at significantly larger scale and across clinical phases.
• Celerion: Early-phase CRO specializing in clinical pharmacology and bioanalytical services with strong preclinical support capabilities. Comparable to Transbiotech's bioanalysis and preclinical pharmacology offerings, particularly for small-molecule and biologics sponsors requiring PK/PD expertise.
• Inotiv: Preclinical CRO and research models provider specializing in animal model studies, toxicology, and safety assessment. Comparable to Transbiotech's CCPA-accredited in vivo pharmacology and toxicology services, though Inotiv operates primarily in U.S. and European markets.
• Biotrial: European-based preclinical and early clinical CRO offering integrated drug development services. Comparable to Transbiotech's preclinical CRO capabilities including pharmacology, safety assessment, and bioanalysis, though Biotrial has stronger clinical phase capabilities.

Broad incumbents

• Charles River Laboratories: Global CRO with extensive preclinical services including animal models, safety assessment, and bioanalysis. Directly comparable to Transbiotech's core offerings of in vivo pharmacology and bioanalytical services, but operates at massive global scale with much broader therapeutic area coverage.
• WuXi AppTec: Global CRO/CDMO providing comprehensive preclinical, clinical, and bioanalytical services. Overlaps significantly with Transbiotech's preclinical CRO offerings but operates at vastly larger scale with global footprint and integrated drug development platform.
• Eurofins Scientific: Global bioanalytical and preclinical testing services provider with extensive laboratory network. Comparable to Transbiotech's bioanalytical chemistry capabilities and preclinical testing services, though Eurofins operates globally with much broader service portfolio.
• Labcorp Drug Development: Major global CRO (formerly Covance) offering preclinical, clinical, and central laboratory services. Directly comparable to Transbiotech's preclinical CRO and bioanalytical offerings, but at much larger scale with extensive therapeutic area and global reach.
• ICON plc: Global CRO providing clinical, bioanalytical, and preclinical research services. Comparable to Transbiotech's bioanalytical and preclinical offerings, though ICON's primary focus is on clinical trials and operates at significantly larger scale.
• SGS (Life Sciences): Global testing, inspection, and certification company with life sciences division offering preclinical and bioanalytical services. Comparable to Transbiotech's bioanalytical chemistry and preclinical testing capabilities, though SGS operates much broader portfolio across multiple industries.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/transbiotech
• Xx.com/TransBIOTech
• Facebookfacebook.com/transbiotech

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Transbiotech